Therapeutic antibodies need to be highly resistant to aggregation due to the high concentrations required for subcutaneous delivery and the potential immunogenicity of antibody aggregates. Human antibody fragments-such as single-domain antibodies (V H or V L )-are typically much less soluble than full-length antibodies. Nevertheless, some aggregation-resistant V H domains have been discovered that are negatively charged at neutral pH and/or enriched in negatively charged residues within the complementarity-determining regions (CDRs). To better understand how to engineer diverse domain antibodies to resist aggregation, we have investigated the solubilizing activity of positively and negatively charged mutations within hydrophobic CDRs of multiple V H scaffolds that differ in their net charge. We find that negatively charged mutations inserted near the edges of hydrophobic CDRs are more effective than positively charged ones at inhibiting aggregation for V H scaffolds that are negatively or near-neutrally charged. In contrast, positively charged CDR mutations prevent aggregation better than negatively charged ones for a V H scaffold that is highly positively charged. Our findings suggest that the net charge of the antibody scaffold is a key determinant of the optimal CDR mutations for preventing aggregation. We expect that our findings will improve the design of aggregation-resistant antibodies with single-and multidomain scaffolds.
Introduction
Monoclonal antibodies (mAbs) are attractive therapeutic agents for treating a wide range of human disorders given the relative ease of discovering antibody variants with high binding affinity and specificity for target molecules. These large, multidomain proteins generally have outstanding biophysical properties, including high folding stability and solubility that are well suited for therapeutic applications. Nevertheless, these well-behaved proteins at low concentrations have variable and difficult-to-predict properties at the high concentrations (.50 mg/ml) required for subcutaneous delivery (Shire, 2009) . Thus, it is critical to develop systematic protein engineering approaches for improving the biophysical properties of antibodies to enhance their use in diverse therapeutic applications (Honegger, 2008; Lowe et al., 2011; Perchiacca and Tessier, 2012; Lee et al., 2013) .
The fact that the variable heavy (V H ) and light (V L ) domains of mAbs are solely responsible for binding to antigens suggests that antibody fragments-such as isolated V H or V L domains or fusions thereof (e.g. single-chain variable fragments or scFvs)-should retain at least some of the binding activity of their parent antibodies. Indeed, single-and multidomain antibody fragments have been reported that bind to target molecules with affinities that rival full-length antibodies (Ward et al., 1989; Clackson et al., 1991) . However, unlike full-length antibodies, antibody fragments generally have poor biophysical properties (e.g. high propensity to aggregate) even at relatively low antibody concentrations (Jespers et al., 2004a,b) , which is one of the reasons why they have not found widespread use in either detection or therapeutic applications.
Several in vitro display methods such as phage display have been used to improve the poor biophysical properties of domain antibodies (dAbs) (Davies and Riechmann, 1996; Reiter et al., 1999; Bond et al., 2003; Jespers et al., 2004a,b; To et al., 2005; Barthelemy et al., 2008; Arbabi-Ghahroudi et al., 2009a,b; Dudgeon et al., 2009 Dudgeon et al., , 2012a . For example, Winter and co-workers reported a powerful phage display method in which libraries of human V H dAbs with sequence variation only in the complementarity-determining regions (CDRs) are displayed on the tips of phage particles in a multivalent manner (Jespers et al., 2004a) . After heating the phage particles to 808C and cooling them to room temperature, rare dAbs were selected that resist aggregation during the heating and cooling steps. Interestingly, the selected dAbs typically had acidic isoelectric points due to enrichment in negatively charged residues within their CDRs, while the aggregationprone germline dAb has a near-neutral isoelectric point. Related phage display studies have also found that aggregationresistant V H dAbs are generally enriched in negatively charged residues in their CDRs and/or scaffolds (Arbabi-Ghahroudi et al., 2009b; Dudgeon et al., 2009) , and that positively charged mutations in the CDRs of V H dAbs are less solubilizing than negatively charged ones (Dudgeon et al., 2012b) .
These interesting observations may suggest that negatively charged mutations are superior to positively charged ones at preventing aggregation for diverse dAbs. Alternatively, these findings may be dependent on the specific scaffolds and/or CDRs used in these studies. For example, positively charged CDR mutations may be most solubilizing for positively charged antibody scaffolds due to electrostatic repulsion. To better define the solubilizing activity of positively and negatively charged mutations in the CDRs of human V H dAbs, we have systematically inserted both types of charged mutations near the edges of hydrophobic CDRs in dAbs specific for the Alzheimer's Ab peptide. We have previously reported that V H dAbs displaying hydrophobic peptides from the Ab peptide in their third CDR (CDR3)-which are named 'gammabodies' for Grafted AMyloid-Motif AntiBODIES-bind to Ab oligomers and fibrils with submicromolar affinity (Perchiacca et al., 2012b) . These V H dAbs are poorly soluble due to the solvent-exposed hydrophobic residues in CDR3. We previously found that inserting negatively charged residues at the edges of CDR3 eliminates aggregation for a V H scaffold with a low net charge at neutral pH (Perchiacca et al., 2012a) . Here, we investigate the effectiveness of positively charged CDR mutations relative to negatively charged ones for different V H scaffolds to evaluate how the solubilizing activity of charged mutations in the CDRs is influenced by the net charge of the antibody scaffold.
Materials and methods

Antibody engineering, expression and purification
Genes for the wild-type and charged dAbs were created using polymerase chain reaction-based gene synthesis (Hoover and Lubkowski, 2002) and ligated into a pET-17b plasmid (Novagen) between the NdeI and XhoI restriction sites. BamHI and NotI restriction sites were introduced at the edges of CDR3 for rapid cloning of CDR variants by ligation of synthetic primer pairs between the two restriction sites. A PelB leader sequence was added to the gene for periplasmic expression. A triple FLAG tag and 7Â His-tag were added to the C-terminus for detection and purification, respectively.
The dAbs were expressed in bacteria [BL21(DE3)pLysS, Stratagene] that were grown in autoinduction media (Studier, 2005) . Both ampicillin (100 mg/ml) and chloramphenicol (35 mg/ml) were added to the media to prevent contamination. The cultures (200 ml in 1 l flask) were grown at 308C (shaken at 250 rpm) for 2 -4 days, pelleted without lysis and the cell pellets were discarded. A shorter expression time (2 days) was used for dAbs with negatively charged scaffolds and/or CDR mutations, while a longer expression time (4 days) was used for dAbs with positively charged scaffolds and/or CDR mutations (for dAbs with two or three positively charged CDR mutations). Nickel agarose beads (2.5 ml; Ni-NTA, Pierce) were added to the cell supernatant and incubated overnight with mild agitation at 158C. The beads were collected by vacuum filtration, and the protein was eluted ( pH 3, phosphate-buffered saline or PBS) and neutralized ( pH 7). The protein purity was confirmed to be .90% by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis (10% acrylamide bis-tris gel; Life Technologies), and the protein concentration was evaluated using the BCA protein assay (Pierce).
Circular dichroism analysis
Circular dichroism spectra (10 mM dAb) were recorded using a Jasco 815 Spectrometer in the far-UV region (200 -250 nm, 1 nm bandwidth, 1 s integration time). Thermal unfolding of each dAb (10 mM) was evaluated by monitoring the ellipticity at 235 nm with a heating rate of 18C/min. The fraction of folded protein was calculated as (Q T 2 Q U )/(Q F 2 Q U ), where Q T is the ellipticity at a given temperature, Q U is the ellipticity of the fully unfolded state and Q F is the ellipticity of the fully folded state of the protein (Greenfield, 2006) .
Tryptophan fluorescence measurements
Protein stability was evaluated by tryptophan fluorescence (l ex ¼ 280 nm, l em ¼ 350 nm) using a Fluorolog-Tau3 (Horiba). Fluorescence at 350 nm (2 nm bandwidth for both excitation and emission) of each dAb was monitored at eight guanidine hydrochloride (GuHCl) concentrations (0 -5 M). Samples were prepared by mixing two dAb preparations (50 mM)-one with and one without 5 M GuHCl-and equilibrating them for 30 min prior to the fluorescence measurements. The recorded fluorescence was then fit to a two-state cooperative equilibrium model (Santoro and Bolen, 1988) .
Antibody solubility analysis
The native solubility of each dAb was evaluated by incubating antibody solutions (50 -60 mM) for at least 1 week at 258C (1Â PBS, pH 7.4). Samples of each dAb were collected periodically, and the concentration of soluble protein was assessed by sedimenting (10 000 g) each sample and quantifying the supernatant concentration with the BCA protein assay (Pierce). To evaluate the non-native solubility, dAbs were prepared at 15 mM, and heated to 60-958C for 20 min. After cooling to 258C for 20 min, each sample was sedimented (1200 g) and the concentration of soluble protein in the supernatant was quantified using the BCA protein assay (Pierce).
Size-exclusion chromatography
A Waters 600 HPLC system and an analytical TSK Gel G3000SWxl column (0.78 Â 30 cm 2 , Tosoh Bioscience) were used to perform size-exclusion chromatography. The dAbs were prepared at 50-60 mM, and 100 ml of each sample was injected at a flow rate of 0.5 ml/min. A Waters 2476 series UV absorbance detector was used to monitor the protein elution at 280 nm.
Antibody binding analysis
The relative binding activity of each dAb was measured in terms of the IC 50 concentration of antibody binding to amyloid fibrils of the Ab42 peptide (American Peptide). Ab fibrils were formed by dissolving Ab42 peptide overnight in neat hexafluoroisopropanol ( 100 mM Ab), evaporating the solvent (.8 h), dissolving the dried Ab in 50 mM NaOH ( 200 mM Ab) for 30 min, filtering (!100 ml of solution; 0.22 mm polyvinylidene difluoride syringe filter, SLGV004SL, Millipore) and diluting the peptide in acidified PBS to yield 25 mM Ab at pH 7.4. The peptide was then centrifuged (208 000 g for 30 min at 48C), and the supernatant (top 85%) was removed and used without further purification. The peptide was assembled into fibrils for 24 h at 378C without agitation in low-retention microcentrifuge tubes (02-681-320, Thermo Fisher Scientific), and the resulting fibrils (500 ml) were sonicated (100% power) on ice for 3 Â 10 s (FB-120 Sonic Dismembrator, Thermo Fisher Scientific) with the sonicator tip submerged in the fibril sample. The sonicated fibrils were diluted to 2.5 mM and immobilized overnight at room temperature in 96-well microtiter plates (Nunc Maxisorb, Thermo Fisher) with 100 ml per well. The wells were then blocked (200 ml of 10% wt/vol milk in PBS for 12 h at room temperature) without removing unbound fibrils (total volume of 300 ml), and then the wells were triple rinsed with PBS. Next, the dAbs were added to the well plates at a range of concentrations (10 -5000 nM), and allowed to bind for 12 h at room temperature. After the unbound dAb was removed via triple rinsing with PBS, the bound dAb was detected via its C-terminal FLAG tags using primary (anti-FLAG, F3165, Sigma-Aldrich) and appropriate horseradish peroxidaseconjugated secondary antibodies. The anti-FLAG ( 1 mg/ml stock concentration) and secondary ( 10 mg/ml stock concentration) antibodies were diluted 1000Â, and each antibody was incubated in the well plates for a relatively short time (20 min per antibody). Finally, the bound secondary antibody was detected using a peroxidase substrate (1-Step Ultra TMB-ELISA, Thermo Fisher Scientific) that was incubated in the microtiter plates (100 ml per well) for 1 -2 h at room temperature. The samples were then quenched with acid (100 ml of 2 M H 2 SO 4 per well), and the absorbance was measured at 450 nm using a Tecan Safire 2 plate reader.
Results
Negatively charged CDR3 mutations prevent dAb aggregation
To evaluate the solubilizing activity of charged insertion mutations within hydrophobic CDRs, we employed two singledomain (V H ) antibodies highlighted in Fig. 1 . These dAbs are identical except that their CDR3 loops contain different hydrophobic Ab peptides (Ab residues 18-VFFAEDVGSN-27 for the Ab18-27 dAb and 33-GLMVGGVVIA-42 for the Ab33-42 dAb). These hydrophobic CDRs mediate dAb binding to Ab aggregates as well as dAb self-aggregation (Perchiacca et al., 2012a) . Thus, we first evaluated how negatively charged mutations inserted at the edges of CDR3-without removing any CDR residues-influence the solubility of the Ab18-27 dAb. Our previous work revealed that this dAb has an aggregation hotspot at the N-terminus of CDR3 (Ab residues 18-VFFA-21), and inserting a triad of negatively charged residues (Asp-Glu-Asp) adjacent to the hydrophobic segment eliminated dAb aggregation (Perchiacca et al., 2012a) .
To investigate this solubilizing activity in more detail, we first generated Ab18-27 dAbs with one, two or three Asp residues inserted at the N-terminus of CDR3 (between Ser96 and Val97; Fig. 1A ). The expression level of the Ab18-27 dAbs increased with increasing number of charged residues from 21 mg/l for the wild-type dAb to 45 mg/l for the triple Asp mutant (Table I ). Circular dichroism revealed that the charged mutants possess similar secondary structures as the wild-type dAb ( Supplementary Fig. S1 ), and tryptophan fluorescence analysis revealed that the wild-type and mutant dAbs possess similar folding stabilities (DG N2U ¼ 47-49 kJ/mol; Table I ).
Nevertheless, the wild-type and charged Ab18-27 mutants possess unique propensities to aggregate (Fig. 2) . We first evaluated the ability of Ab18-27 dAbs to reversibly unfold Yield (mg/l) was calculated using 200 ml bacterial cultures. Aggregation-resistant domain antibodies using circular dichroism ( Fig. 2A) . The wild-type and single Asp mutant aggregated when unfolded, as judged by the difference in the unfolding transitions between the first and second melts for the same dAb sample. In contrast, the double and triple Asp mutants display reversible unfolding transitions, suggesting that the Asp mutations protect the Ab18-27 dAb against aggregation when unfolded. We also evaluated this finding by quantifying the amount of soluble antibody after transiently heating the Ab18-27 dAbs (Fig. 2B) . The double and triple Asp variants fail to aggregate even when heated to 958C, while the wild-type dAb is the least soluble and the single Asp variant displays an intermediate solubility.
It was unnecessary to heat the dAb samples to observe these dramatic differences in solubility, as storing them at room temperature for 1 week revealed similar behavior (Fig. 2C ). These differences in solubility are consistent with the size-exclusion behavior of the Ab18-27 dAbs, as the wild-type dAb sticks to the column, and the charge variants display improved behavior with increasing number of charged mutations (Fig. 2D ). More importantly, inserting three Asp residues at the C-terminus of CDR3 (between Asn100f and Ala100g; Fig. 1A ) was much less effective at preventing aggregation ( Supplementary  Fig. S2 ), confirming that the aggregation hotspot is located at the N-terminus of CDR3 (Perchiacca et al., 2012a). We also investigated whether glutamic acid mutations would display similar or unique solubilizing activity relative to aspartic acid mutations when inserted adjacent to the aggregation hotspot in CDR3 of the Ab18-27 dAb. These studies are motivated by a recent report that Asp mutations in the CDRs of related V H dAbs are more solubilizing than Glu mutations (Dudgeon et al., 2012b) . Therefore, we generated Ab18-27 dAb variants with one, two or three Glu residues inserted at the N-terminus of CDR3 (at the same position used to generate the Asp variants). The Glu mutants expressed at similar levels as the Asp mutants, and display similar secondary structures and folding stabilities as both the Asp mutants and the wild-type dAb (Table I and Supplementary Fig. S3 ). Moreover, the solubility and size-exclusion results for the Glu mutants ( Fig. 3 and Supplementary Fig. S3 ) were similar to those for their Asp counterparts (Fig. 2) , revealing that the Asp and Glu mutations display similar solubilizing activity for the Ab18-27 dAb. We also confirmed that inserting one, two or three Ala residues at the same position within CDR3 had no effect on dAb solubility ( Supplementary Fig. S3 ), confirming that simply making CDR3 longer with insertion mutations does not reduce aggregation. Finally, inserting Glu mutations at the C-terminus of CDR3 only partially prevented aggregation of Ab18-27 dAbs ( Supplementary Fig. S4 ) in a manner similar to that observed for the Asp mutations at the same positions ( Supplementary Fig. S2 ).
Positively charged CDR3 mutations weakly inhibit dAb aggregation
Our findings suggest that electrostatic repulsion between negatively charged residues adjacent to hydrophobic residues potently prevents aggregation. Thus, we investigated whether positively charged mutations (Lys or Arg) at the same positions within hydrophobic CDRs would also prevent aggregation. We generated Ab18-27 dAbs with one, two or three Lys/ Arg residues inserted at the N-terminus of CDR3. The expression levels of the mutant dAbs (9 -19 mg/l) were lower than the wild-type Ab18-27 dAb (21 mg/l), and decreased with increasing number of Lys/Arg mutations (Table II) . This may suggest that the positively charged mutations destabilize the Ab18-27 dAb. However, the mutant dAbs have similar secondary structures and folding stabilities as their parent dAb (Table II and Supplementary Fig. S5 ), which suggests that the reduced expression was due to factors other than reduced antibody stability.
Notably, the positively charged CDR3 mutations were less effective at preventing aggregation of the Ab18-27 dAb than the negatively charged ones (Fig. 4 and Supplementary  Fig. S5 ). The native (Fig. 4A and B) and non-native ( Supplementary Fig. S5 ) solubilities of dAbs with Arg or Lys mutations increased modestly with increasing number of mutations. However, triple Arg or Lys mutations were unable to eliminate aggregation, and their size-exclusion behaviors were inferior (Fig. 4C) to those of the Ab18-27 dAbs with triple Glu or Asp mutations ( Figs 2D and 3B ). The partial solubilizing activity of the positively charged mutations at room temperature was reduced if the triple Arg or Lys mutations were moved to the C-terminus of CDR3 ( Supplementary  Fig. S6 ), as observed for the negatively charged mutations (Supplementary Fig. S2 ). However, the relatively low nonnative solubilities of the Ab18-27 dAbs were similar regardless of whether the triple Lys or Arg mutations were inserted at the N-or C-terminus of CDR3 (Supplementary Fig. S6 ). This reveals that the positively charged mutations weakly prevented non-native dAb aggregation in a manner independent of their location within CDR3.
The Ab18-27 dAb contains three repeats of the negatively charged FLAG-tag peptide (residues DYKDDDDK) near its Yield (mg/l) was calculated using 200 ml bacterial cultures.
c Apparent melting temperature (dAb aggregated irreversibly upon unfolding).
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C-terminus for detection purposes in antibody binding assays. Thus, it is possible that the Arg and Lys CDR3 mutations are only weakly solubilizing due to attractive electrostatic interactions between positively charged CDR loops and negatively charged FLAG tags that may promote antibody aggregation.
To evaluate this possibility, we generated Ab18-27 dAbs without FLAG tags that have triple Arg and Asp mutations at the N-terminus of CDR3. Importantly, removing the FLAG tags does not increase the solubility of the triple Arg mutant of the Ab18-27 dAb, but instead results in similar solubility and poorer size-exclusion behavior ( Supplementary Fig. S7 ). This finding suggests that the weak solubilizing activity of positively charged CDR mutations is not due to attractive electrostatic interactions involving the FLAG tags. Removal of the FLAG tags from the triple Asp mutant also results in similar dAb solubility and inferior size-exclusion behavior ( Supplementary Fig. S7 ). This is consistent with previous reports that the FLAG-tag peptide increases the hydrophilicity of diverse proteins (Einhauer and Jungbauer, 2001; Waugh, 2005; Kvam et al., 2010) .
Negatively charged CDR mutations prevent dAb aggregation for multiple CDR3 sequences
We next evaluated the generality of our findings for a second dAb (Ab33-42) with a significantly different CDR3. While the CDR3 sequence of the Ab18-27 dAb (residues 18-VFFAEDVGSN-27) contains aromatic (Phe19 and Phe20) and charged (Glu22 and Asp23) residues, the CDR3 of the Ab33-42 dAb (residues 33-GLMVGGVVIA-42) contains neither. We previously identified an aggregation hotspot at the C-terminus of CDR3 for the Ab33-42 dAb (residues 39-VVIA-42) (Perchiacca et al., 2012a) . Therefore, we generated Ab33-42 dAbs with one, two or three Asp/Arg mutations inserted at the C-terminus of CDR3 (between Ala100f and Ala100g; Fig. 1A ). As observed for the Ab18-27 dAb, the expression level was the highest for the triple Asp mutant (47 mg/l) and lowest for the triple Arg mutant (10 mg/l; Table III ). The differences in expression levels of the Ab33-42 dAbs did not correspond to differences in their secondary structures (data not shown) or folding stabilities (Table III) . Despite these similarities, the Ab33-42 dAbs display dissimilar solubilities. The native (Fig. 5A ) and non-native ( Supplementary Fig. S8 ) solubilities of the Asp mutants increase with increasing number of Asp residues, and the double and triple Asp mutants eliminate aggregation. The Arg mutants also display increasing solubility with increasing number of Arg residues (Fig. 5B ), but the triple Arg mutant is less soluble than its triple Asp counterpart (and displays inferior size-exclusion behavior; Fig. 5C ). We also observed similar behavior for Ab33-42 dAbs with Glu and Lys insertion mutants at the C-terminus of CDR3 (Supplementary Fig. S8 ). In contrast, Ala insertion mutations at the same positions within CDR3 do not increase the solubility or improve the size-exclusion behavior of the Ab33-42 dAbs ( Supplementary  Fig. S8 ). Moreover, inserting positively (triple Arg) or negatively (triple Asp) charged mutations at the N-terminus of CDR3 fails to prevent aggregation of Ab33-42 dAbs ( Supplementary Fig. S9 ). Finally, removal of the FLAG-tag peptides from the C-terminus of the Ab33-42 dAbs modestly reduces the solubility of variants with positively charged CDR mutations, and worsens the size-exclusion behavior of dAbs with either positively or negatively charged CDR mutations (Supplementary Fig. S10 ). This finding is consistent with the results for the Ab18-27 dAbs ( Supplementary Fig. S7 ), and strengthens our observation that FLAG tags increase the hydrophilicity of dAbs with either positively or negatively charged CDR mutations.
Positively charged CDR3 mutations maximize solubility for a positively charged V H scaffold
Our findings demonstrate that negatively charged mutations are more solubilizing than positively charged ones for a V H scaffold with a low net charge [theoretical net charge of þ1.9 at pH 7, 7 Glu þ Asp and 9 Arg þ Lys, and theoretical isoelectric point ( pI) of 8.5 when omitting the CDRs and FLAG tags]. Moreover, these findings appear largely independent of the sequence of CDR3, as similar behavior was observed for two dissimilar hydrophobic CDR3s (Ab18-27 and Ab33-42). Nevertheless, we suspected that the superior solubilizing activity of negatively charged CDR mutations is dependent on the net charge of the V H scaffold. More specifically, we expected that increasing the net positive charge of the V H scaffold would enhance the solubilizing activity of positively charged CDR mutations relative to negatively charged ones due to electrostatic repulsion. In contrast, we expected that making the V H scaffold negatively charged would maintain the superior solubilizing activity of negatively charged CDR mutations relative to positively charged ones.
To test these hypotheses, we identified the most solventexposed residues outside of the CDRs using multiple algorithms (Ahmad et al., 2004; Cheng et al., 2005) , and introduced several neutral-to-charged and charge reversal mutations. For the scaffold with increased positive charge, we introduced seven mutations (L11R, G26R, S74R, E85R, A94R, Q105K and S112R) to obtain a scaffold with a theoretical net charge of þ9.9 at neutral pH (6 Glu þ Asp and 16 Arg þ Lys, and theoretical pI of 10.7 when omitting the CDRs and FLAG tags). For the negatively charged scaffold, we introduced six mutations (L11D, G26E, K43D, K64D, Q105E and S112D) to obtain a scaffold with a theoretical net charge of 26.1 at neutral pH (13 Glu þ Asp and 7 Arg þ Lys, and theoretical pI of 4.4 when omitting the CDRs and FLAG tags).
Next, we introduced the hydrophobic Ab33-42 CDR3 into both positively and negatively charged scaffolds with triple Asp, Arg or Ala mutations at the C-terminus of CDR3. The expression levels of the dAbs with Asp CDR mutations (26 and 15 mg/l for the negatively and positively charged scaffolds, respectively) were similar to those with Ala CDR mutations (20 and 16 mg/l for negatively and positively charged scaffolds, respectively) and higher than those with Arg CDR mutations (10 mg/l for both scaffolds; Table IV ). The stabilities of dAbs with either scaffold (DG N2U ¼ 32-36 kJ/mol and apparent T m ¼ 69 -718C; Table IV) were lower than for the wildtype Ab33-42 dAb (DG N2U ¼ 48 + 1.7 kJ/mol and apparent T m ¼ 78 + 1.58C; Table III ). Nevertheless, the secondary structures of the dAbs with positively and negatively charged scaffolds were similar to the wild-type Ab33-42 dAb ( Supplementary Fig. S11 ).
The similar stabilities and secondary structures of Ab33-42 dAbs with positively and negatively charged scaffolds enabled us to directly compare the effectiveness of positively and negatively charged CDR mutations for preventing aggregation (Fig. 6) . For the negatively charged scaffold, we find that triple Asp mutations prevent native (Fig. 6A ) and non-native Aggregation-resistant domain antibodies (Supplementary Fig. S11 ) aggregation, and correspond to excellent size-exclusion behavior (Fig. 6B) . In contrast, positively charged mutations (triple Arg) partially inhibit aggregation ( Fig. 6A) with similar effectiveness as the same mutations in the wild-type scaffold (Fig. 5B) . However, the size-exclusion behavior of the triple Arg mutant is modestly worse (as judged by the number of peaks) for the negatively charged scaffold (Fig. 6B) relative to the corresponding dAb with a wild-type scaffold (Fig. 5C) . The triple Ala mutant of the same dAb with a negatively charged scaffold was more soluble (Fig. 6A ) than its counterpart with a wild-type scaffold ( Supplementary  Fig. S8 ), revealing that the negatively charged scaffold increases the solubility of dAbs with hydrophobic CDRs that are uncharged.
Importantly, the positively charged scaffold displays significantly different behavior than the negatively charged one (Fig. 6C and D) . Notably, the triple Arg mutant with a positively charged scaffold displays modestly improved native solubility (Fig. 6C ) and size-exclusion (Fig. 6D ) results relative to those for the triple Asp mutant. Moreover, the size-exclusion behavior of the triple Asp mutant with a positively charged scaffold (Fig. 6D) is significantly worse than the corresponding dAbs with negatively (Fig. 6B) or nearneutrally charged (Fig. 5C ) scaffolds. The native solubility results for the triple Ala mutant with a positively charged scaffold (Fig. 6C) were similar to those for the corresponding dAb with a negatively charged scaffold (Fig. 6A) and improved relative to those for the corresponding dAb with an uncharged scaffold ( Supplementary Fig. S8 ). These findings reveal that the positively charged scaffold also improves the solubility of dAbs with hydrophobic CDRs that are uncharged, as observed for the negatively charged scaffold (Fig. 6A) . Overall, our findings suggest that the optimal charged mutations for maximizing dAb solubility are dependent on the charge of the V H scaffold.
Charged insertion mutations in CDR3 do not alter dAb binding affinity
A significant concern with introducing charged mutations into the CDRs of antibodies to improve their solubility is that such (Table V) . These values are modestly higher than previously reported values for the same dAbs (300-400 nM) (Perchiacca et al., 2012a,b) , which may be due to batch-to-batch variability in the preparation of Ab fibrils. Nevertheless, we find that the relative binding affinities of the charged CDR mutants for each Ab dAb are similar to the wildtype dAbs and are independent of the charge of the V H scaffold (Table V) . These findings suggest that antibody solubility can be increased with positively or negatively charged CDR mutations without reducing binding affinity for dAbs with hydrophobic binding loops.
Discussion
Several mutational studies aimed at increasing the solubility of antibody fragments have found that negatively charged mutations are more solubilizing than positively charged ones (Jespers et al., 2004a; Arbabi-Ghahroudi et al., 2009b; Dudgeon et al., 2009 Dudgeon et al., , 2012b Kvam et al., 2010; Perchiacca et al., 2011 Perchiacca et al., , 2012a ), as we observed in this work for negatively and near-neutrally charged V H scaffolds. The finding that negatively charged residues are most solubilizing has also been observed for non-antibody proteins (Trevino et al., 2007; Niwa et al., 2009; Kramer et al., 2012) . Interestingly, the high solubility of proteins from halophilic organisms (which live in high salt environments) appears to be due to their enrichment in negatively charged residues (Dym et al., 1995; Frolow et al., 1996) . The solubilizing activity of Asp and Glu residues may be linked to the kosmotropic nature of their carboxylate group-which leads to favorable interactions with water and increased hydration-relative to the chaotropic nature of the amino (Lys) and guanidino (Arg) groups (Kuntz, 1971; Collins, 1997) . It is notable that the guanidinium cation appears to be one of the most poorly hydrated cations studied to date (Mason et al., 2003 (Mason et al., , 2004 . However, other studies reveal that the optimal polarity of charged mutations for maximizing protein solubility depends on several factors, including the protein net charge (Lawrence et al., 2007; Trevino et al., 2007; Wu et al., 2010; Miklos et al., 2012; Der et al., 2013) and spatial distribution of charge (Zbilut et al., 2004; Long and Labute, 2010; Yadav et al., 2011 Yadav et al., , 2012 Chari et al., 2012) . For example, it is well known that protein solubility is typically lowest at pH values near the pI and highest at pH values far from the pI (either higher or lower pH). Thus, introducing positively charged mutations into proteins with strongly basic pIs should improve their solubility at near-neutral pH better than negatively charged mutations, as we observed for the highly positively charged V H scaffold ( Fig. 6 and Supplementary Fig. S11 ). Moreover, supercharging proteins (such as green fluorescent protein) by substituting a large number of solvent-exposed residues with charged residues of the same polarity results in highly aggregation-resistant proteins for both positively and negatively charged variants (Lawrence et al., 2007; Der et al., 2013) .
The spatial distribution of charged residues is also a critical determinant of protein solubility due to potential attractive electrostatic interactions between oppositely charged patches on protein surfaces that may reduce solubility (Lomakin et al., 1999; Zbilut et al., 2004; Long and Labute 2010; Yadav et al., 2011 Yadav et al., , 2012 Chari et al., 2012) . Indeed, we find that the solubility of the Ab33-42 dAb with a positively charged scaffold and negatively charged (triple Asp) CDR mutations ( Fig. 6 and Supplementary Fig. S11 ) was lower than that for similar dAbs with negatively or near-neutrally charged V H scaffolds ( Fig. 5 and Supplementary Fig. S8 ). Moreover, when we inserted positively charged residues at one edge of CDR3 and negatively charged ones at the other edge of the same CDR, the solubility was dramatically reduced (data not shown). These findings suggest that attractive electrostatic interactions between oppositely charged patches on the surface of V H domains reduce dAb solubility.
Our finding that the optimal charged mutations that prevent dAb aggregation are dependent on the net charge of the antibody scaffold may provide (at least in part) an explanation for some disparate observations in the previous work. Many of the previous mutational studies of single-domain antibodies used scaffolds that are negatively or near-neutrally charged at neutral pH (Jespers et al., 2004a,b; Arbabi-Ghahroudi et al., 2009b; Dudgeon et al., 2009 Dudgeon et al., , 2012b Perchiacca et al., 2011 Perchiacca et al., , 2012a , which may explain why negatively charged mutations were optimal. In contrast, analysis of a scFv scaffold that is positively charged (theoretical net charge of þ7.5 at neutral pH) revealed that positively charged mutations were most solubilizing (Miklos et al., 2012) . Future work will need to evaluate our speculative hypothesis and identify if exceptions exist due to factors such as the spatial distribution of oppositely charged residues on antibody surfaces.
Our work also revealed an important practical issue related to the expression of dAbs with clusters of charged mutations. Interestingly, the largest difference that we observed between dAbs with positively and negatively charged CDR mutations was their expression levels. While inserting more negatively charged mutations into CDR3 led to higher expression levels, the opposite was observed for positively charged mutations (i.e. expression levels were progressively reduced with increasing number of consecutive Arg/Lys mutations). In fact, we had to double the expression time for dAbs with two or three positively charged CDR mutations in order to obtain a sufficient quantity of antibody, which was still half of that obtained for the wild-type dAbs. Our findings suggest that this reduced expression was not due to increased aggregation propensities or unusually low stabilities of dAbs with positively charged CDR mutations. Instead, the poor expression is likely due to poor dAb translocation across the cytosolic membrane (which is necessary for folding in the periplasm), as observed for other positively charged proteins (Wilson and Finlay, 1998) . This limitation can be overcome (at least in part) by using engineered bacterial strains that have an oxidizing cytoplasm to enable antibody folding and disulfide bond formation without the need for translocation into the periplasm (Bessette et al., 1999; Miklos et al., 2012) . Several other findings from our work appear to contribute to the long-standing goal of designing aggregation-resistant antibodies. First, the conformational stabilities of the Ab dAbs were unrelated to their native and non-native solubilities. In hindsight, this is logical because the hydrophobic CDRs that mediate dAb aggregation are expected to be solvent-exposed in their folded and unfolded states, and should not require unfolding to cause aggregation. This is an important consideration when attempting to improve the solubility of other aggregation-prone antibody fragments, as improving conformational stability may not improve native solubility if aggregation is mediated through residues that are solvent-exposed in the native state (Chi et al., 2003; Chennamsetty et al., 2009; Pepinsky et al., 2010; Wu et al., 2010; Perchiacca and Tessier, 2012; Perchiacca et al., 2012a) . Secondly, we find that charged mutations could be inserted near the edges of CDR3 to prevent aggregation without reducing binding affinity. Notably, we did not use substitution mutations to eliminate hydrophobic CDR residues that may be involved in binding (Wu et al., 2010) . This mutational strategy may be useful for other antibody fragments and full-length antibodies, especially for those with hydrophobic CDRs and for which other mutational strategies are ineffective. Thirdly, the solubilizing activity of charged mutations within hydrophobic CDRs is highly dependent on their location within CDR3, and the most effective location for such mutations is dependent on the CDR sequence. It was only possible to prevent aggregation of the Ab18-27 dAb with charged mutations at the N-terminus of CDR3, while the opposite was true for the Ab33-42 dAb. These findings can be rationalized based on the proximity of charged mutations relative to the most hydrophobic regions within CDR3, and the identification of optimal locations for charged CDR mutations can be guided by various computational methods (Linding et al., 2004; Conchillo-Sole et al., 2007; Trovato et al., 2007; Chennamsetty et al., 2009; Wang et al., 2009 Wang et al., , 2010 Maurer-Stroh et al., 2010; Goldschmidt et al., 2011; Buck et al., 2012) . We are currently working to evaluate whether these and other findings from this work can be used to improve the design of aggregation-resistant multidomain antibody fragments and full-length antibodies.
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